TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model

BCMA-directed CAR-T therapies have shown promising results in multiple myeloma (MM). However, patients continue to relapse. T cell exhaustion with increased TIGIT expression is a resistance mechanism which was confirmed in CAR-T cells from ARI0002h trial, an academic CAR-T developed in our instituti...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Aina Oliver-Caldes, Joan Mañe Pujol, Anthony M. Battram, Lorena Perez-Amill, Mireia Bachiller, Hugo Calderon, Maria Castella, Judit Carpio, Sergi V. Salsench, Natalia Tovar, Oriol Cardus, Alvaro Urbano-Ispizua, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Ester Lozano, Laura Rosiñol, Manel Juan, Beatriz Martín-Antonio, Carlos Fernández de Larrea
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2025-12-01
Saila:	OncoImmunology
Gaiak:	CAR-T cell therapy multiple myeloma TIGIT blockade BCMA-CAR-T CRISPR/Cas9 4th generation CAR-T
Sarrera elektronikoa:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2529632
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!